Achillion Pharmaceuticals (NASDAQ:ACHN) has been given an average recommendation of “Hold” by the ten research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $5.20.
A number of research analysts recently commented on ACHN shares. Zacks Investment Research upgraded shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, February 27th. BidaskClub upgraded shares of Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, December 21st. Finally, B. Riley started coverage on shares of Achillion Pharmaceuticals in a research note on Thursday, February 8th. They set a “neutral” rating and a $3.50 price objective on the stock.
ACHN opened at $3.84 on Wednesday. The company has a market cap of $490.90, a PE ratio of -6.19 and a beta of 0.89. Achillion Pharmaceuticals has a twelve month low of $2.58 and a twelve month high of $5.66.
Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.01). During the same quarter last year, the business posted ($0.03) EPS. sell-side analysts forecast that Achillion Pharmaceuticals will post -0.55 EPS for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. RTW Investments LP grew its position in Achillion Pharmaceuticals by 72.8% in the fourth quarter. RTW Investments LP now owns 13,546,902 shares of the biopharmaceutical company’s stock worth $39,015,000 after buying an additional 5,707,136 shares during the last quarter. BlackRock Inc. grew its position in Achillion Pharmaceuticals by 17.7% in the fourth quarter. BlackRock Inc. now owns 11,572,015 shares of the biopharmaceutical company’s stock worth $33,326,000 after buying an additional 1,736,124 shares during the last quarter. BVF Inc. IL acquired a new position in Achillion Pharmaceuticals in the fourth quarter worth approximately $4,632,000. Dimensional Fund Advisors LP grew its position in Achillion Pharmaceuticals by 75.3% in the third quarter. Dimensional Fund Advisors LP now owns 3,276,076 shares of the biopharmaceutical company’s stock worth $14,710,000 after buying an additional 1,407,108 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in Achillion Pharmaceuticals by 128.8% in the fourth quarter. Renaissance Technologies LLC now owns 2,182,467 shares of the biopharmaceutical company’s stock worth $6,286,000 after buying an additional 1,228,492 shares during the last quarter. Institutional investors and hedge funds own 82.04% of the company’s stock.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.